Klotho与CKD临床结局:CRIC研究
本研究基于CRIC前瞻性队列1088例eGFR 20-70mL/min/1.73m2的CKD患者,分析第1年血浆Klotho水平与5年全因死亡、心衰住院、动脉粥样硬化心血管事件及复合肾脏终点的关联。结果显示高Klotho组与最低Klotho组相比各结局均无差异,且Klotho缺乏不混淆FGF23与死亡或心衰住院的关联。
要点
- CKD患者血浆Klotho水平与5年全因死亡、心衰住院、心血管事件及肾脏进展均无显著关联。
- FGF23与死亡和心衰住院的关联独立于Klotho水平。
- 血浆Klotho降低可能不驱动CKD不良临床结局。
核心结论
- 在大型CKD队列中,Klotho与临床结局无关联,Klotho缺乏不混淆FGF23与死亡或心衰住院的关联。
研究设计与样本
- 前瞻性观察研究,纳入CRIC研究中1088例eGFR 20-70mL/min/1.73m2的CKD参与者,暴露为第1年研究访视时的血浆Klotho水平。
主要发现
- 平均eGFR为42mL/min/1.73m2,Klotho中位浓度0.31ng/mL(IQR 0.10-3.27ng/mL)。
- 与最低Klotho组相比,高Klotho组生存(HR 0.77;95%CI 0.32-1.89)、心衰住院(HR 1.10;95%CI 0.38-3.17)、动脉粥样硬化心血管事件(HR 1.19;95%CI 0.57-2.52)及CKD进展(HR 1.05;95%CI 0.58-1.91)均无差异。
- FGF23与死亡和心衰住院显著关联,且独立于Klotho水平。
临床怎么用
- 在CKD患者中,血浆Klotho水平不宜作为预测死亡、心衰住院、心血管事件或肾脏进展的独立标志物。
- 评估CKD患者死亡和心衰住院风险时,FGF23的关联不受Klotho水平影响。
局限性
- 尽管进行了调整,不能排除残余混杂或样本储存对结果的潜在影响。
- 单次血浆Klotho浓度测量可能无法反映Klotho随时间的变化模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Klotho deficiency may affect clinical outcomes in chronic kidney disease (CKD) through fibroblast growth factor-23 (FGF23)-dependent and -independent pathways. However, the association between circulating Klotho and clinical outcomes in CKD remains unresolved and was the focus of this study. STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 1,088 participants in the Chronic Renal Insufficiency Cohort (CRIC) Study with an estimated glomerular filtration rate (eGFR) of 20-70mL/min/1.73m2. EXPOSURE: Plasma Klotho level at the year-1 study visit. OUTCOMES: 5-year risks of all-cause mortality, heart failure hospitalization, atherosclerotic cardiovascular events, and a composite kidney end point that comprised a sustained 50% decrease in eGFR, dialysis, kidney transplant, or eGFR<15mL/min/1.73m2. ANALYTICAL APPROACH: We divided Klotho into 6 groups to account for its nonnormal distribution. We used Cox proportional hazards regression and subdistribution hazards models to compare survival and clinical outcomes, respectively, between Klotho groups. We sequentially adjusted for demographic characteristics, kidney function, cardiovascular risk factors, sample age, and FGF23. RESULTS: Mean eGFR was 42mL/min/1.73m2, and median Klotho concentration was 0.31ng/mL (IQR, 0.10-3.27ng/mL). When compared with the lowest Klotho group, survival (HR, 0.77; 95% CI, 0.32-1.89), heart failure hospitalization (HR, 1.10; 95% CI, 0.38-3.17), atherosclerotic cardiovascular events (HR, 1.19; 95% CI, 0.57-2.52), and CKD progression (HR, 1.05; 95% CI, 0.58-1.91) did not differ in the high Klotho group. In contrast, FGF23 was significantly associated with mortality and heart failure hospitalization independent of Klotho levels. LIMITATIONS: Despite adjustments, we cannot exclude the potential influence of residual confounding or sample storage on the results. A single measurement of plasma Klotho concentration may not capture Klotho patterns over time. CONCLUSIONS: In a large, diverse, well-characterized CKD cohort, Klotho was not associated with clinical outcomes, and Klotho deficiency did not confound the association of FGF23 with mortality or heart failure hospitalization. PLAIN-LANGUAGE SUMMARY: Klotho is a protein that is vital to mineral metabolism and aging and may protect against cardiovascular disease. Klotho levels decrease in chronic kidney disease (CKD), but the association between Klotho and clinical outcomes in CKD remains uncertain. In a prospective cohort study of more than 1,000 people with CKD, circulating Klotho levels were not associated with kidney disease progression, cardiovascular outcomes, or mortality. These results suggest that the decrease in circulating Klotho levels in CKD does not play a prominent role in the development of poor clinical outcomes.
引用
- Edmonston D, Fuchs MAA, Burke EJ, et al. Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2024. PMID: 38583756. doi:10.1053/j.ajkd.2024.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。